Durham, NC Clinical Trials Report — June 2026

For individuals in Durham, NC, considering participation in clinical research, June 2026 presents a mix of immediate opportunities and promising new avenues for contributing to medical science. A total of 54 clinical trials are slated to conclude enrollment within the next 90 days, making prompt action essential for interested individuals. This urgency is particularly relevant for healthy volunteers, as 14 of these rapidly closing studies are still actively seeking participants without specific health conditions.

New Research Horizons in Durham

This month, Durham saw the opening of 12 new clinical trials, a slight decrease from the 13 trials that launched in May 2026. This brings the total number of actively recruiting clinical trials in Durham, NC, to 939 across 228 research facilities, highlighting the city's significant role in advancing medical knowledge.

June brings several high-profile new trials to Durham, including significant Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, is initiating a notable Phase 3 study, NCT07654361, "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)." This pivotal, multicenter, global, randomized, placebo-controlled, double-blind study aims for 3,600 participants to investigate the long-term efficacy, safety, and tolerability of aleniglipron once daily compared with placebo for chronic weight management.
• Also from Gasherbrum Bio, Inc., NCT07654374, "A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)," is a Phase 3 randomized, double-blind, placebo-controlled study involving 1,100 participants. It will evaluate the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in individuals living with overweight or obesity and Type 2 Diabetes Mellitus.
• Pfizer is sponsoring NCT07629440, "A Study to Learn About How a New Pneumococcal Vaccine Works in Infants." This Phase 3 study seeks 3,230 participants to learn about the safety and effectiveness of a new pneumococcal vaccine in infants, comparing it to an existing vaccine to fight against infections like pneumonia, meningitis, and otitis media.
• AstraZeneca is leading NCT07662213, "A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus." This Phase 3 trial aims for 1,200 participants to evaluate the efficacy, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with Type 2 Diabetes Mellitus and increased cardiovascular risk.
• Vanderbilt University Medical Center is sponsoring NCT07674758, "Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials," involving 1,000 participants. This research seeks to better understand the evolution of heart dysfunction in Duchenne and Becker Muscular Dystrophy patients and carriers.
• Duke University is sponsoring NCT07634419, "Self-directed Mobile Mindfulness to Address ICU Survivors' Psychological Distress," with 450 participants. This study aims to help survivors of serious acute heart and lung illnesses manage lasting depression, anxiety, and stress through mobile mindfulness interventions.

New trials this month are exploring a range of conditions, with a focus on metabolic health. Conditions with new trials include:

• Chronic weight management (2 trials)
• Obesity (2 trials)
• Overweight (2 trials)
• Becker muscular dystrophy (1 trial)
• Body image (1 trial)
• Breast cancer (1 trial)
• Breast reconstruction (1 trial)
• Cardiomyopathy (1 trial)
• Carrier of duchenne muscular dystrophy (1 trial)
• Colorectal cancer (1 trial)

Drug trials account for the largest share of new studies, with 5 new drug trials, followed by 2 behavioral studies. Industry sponsors are driving a significant portion of new research in Durham, with 6 industry-sponsored trials opening this month, alongside 5 academic and 1 federally sponsored study.

Act Now: Trials Closing Soon

Patients managing specific health conditions also face impending deadlines to join research. Trials focused on various neurological and oncological conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Dementia (3 trials)
• Lung cancer (2 trials)
• Metastatic cancer (2 trials)
• Mild cognitive impairment (2 trials)
• Advanced cancer (1 trial)
• Advanced malignant neoplasm (1 trial)
• Acute liver failure (1 trial)
• Astrocytoma (1 trial)
• Acute pain (1 trial)
• Astrocytoma, IDH-mutant (1 trial)

Durham's Leading Research Facilities

Durham is a hub for medical research, largely due to the presence of Duke University's extensive medical network. These facilities consistently run a high volume of clinical trials and are key destinations for individuals seeking to participate in medical research:

• Duke University Medical Center (264 trials)
• Duke University (161 trials)
• Duke University Hospital (50 trials)
• Duke University Health System (42 trials)
• Duke Cancer Institute (38 trials)
• Duke Cancer Center (29 trials)
• Durham VA Medical Center, Durham, NC (23 trials)
• Durham VA Medical Center (19 trials)
• Duke University Eye Center (12 trials)
• Duke University School of Medicine (11 trials)
• Duke Eye Center (10 trials)

These institutions, particularly those affiliated with Duke University, offer a broad spectrum of research opportunities across numerous medical specialties, from oncology to ophthalmology. The Durham VA Medical Center also plays a crucial role, providing research options for veterans.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to research. A total of 2 of the 12 new trials launched this month are actively seeking healthy volunteers. Across Durham, a total of 99 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research. Remember, 14 healthy volunteer trials are closing within the next 90 days, so interested individuals should explore these options soon.

Broadening Your Search: Nearby Options

While Durham offers a robust array of clinical trial opportunities, individuals may also find options in nearby communities within North Carolina. Cities with active trials include Chapel Hill (10 trials), Winston-Salem (9 trials), Charlotte (8 trials), Raleigh (7 trials), Greensboro (6 trials), Wilmington (6 trials), Morehead City (4 trials), and Statesville (3 trials).

Participation in clinical trials is open to a diverse range of individuals. Of the 12 new trials launched this month, 10 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 3 new trials include children, and 1 is female-only. Duke University continues to play a vital role in Durham's research ecosystem, sponsoring 4 of the new studies this month, while industry sponsors like Gasherbrum Bio, Inc., Pfizer, and AstraZeneca are also driving significant research efforts.

As we move through June, Durham's dynamic research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare and improve patient outcomes.